T. Rowe Price Associates
ANGO icon

T. Rowe Price Associates’s AngioDynamics ANGO Stock Holding History

T. Rowe Price Associates’s Portfolio ANGO Stock Details ANGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$554K Buy
48,712
+4,414
+10% +$47.8K ﹤0.01% 2404
2025
Q4 		$569K Buy
44,298
+2,263
+5% +$27.9K ﹤0.01% 2329
2025
Q3 		$470K Buy
42,035
+1,330
+3% +$12.8K ﹤0.01% 2379
2025
Q2 		$404K Buy
40,705
+2,253
+6% +$22.1K ﹤0.01% 2403
2025
Q1 		$362K Buy
38,452
+1,516
+4% +$15.9K ﹤0.01% 2383
2024
Q4 		$339K Buy
36,936
+2,397
+7% +$17.6K ﹤0.01% 2457
2024
Q3 		$269K Buy
34,539
+188
+0.5% +$1.36K ﹤0.01% 2527
2024
Q2 		$208K Buy
34,351
+579
+2% +$3.57K ﹤0.01% 2581
2024
Q1 		$199K Buy
33,772
+2,821
+9% +$16.8K ﹤0.01% 2627
2023
Q4 		$243K Buy
30,951
+5,131
+20% +$35.6K ﹤0.01% 2465
2023
Q3 		$189K Buy
25,820
+5,070
+24% +$42.2K ﹤0.01% 2521
2023
Q2 		$217K Buy
20,750
+642
+3% +$6.18K ﹤0.01% 2494
2023
Q1 		$208K Sell
20,108
-2,240
-10% -$28.7K ﹤0.01% 2509
2022
Q4 		$308K Sell
22,348
-8,636
-28% -$120K ﹤0.01% 2366
2022
Q3 		$634K Sell
30,984
-3,077
-9% -$67.5K ﹤0.01% 2003
2022
Q2 		$659K Buy
34,061
+106
+0.3% +$2.17K ﹤0.01% 2093
2022
Q1 		$731K Sell
33,955
-5,186
-13% -$118K ﹤0.01% 2170
2021
Q4 		$1.08M Sell
39,141
-7,900
-17% -$218K ﹤0.01% 1999
2021
Q3 		$1.22M Buy
47,041
+135
+0.3% +$3.61K ﹤0.01% 1951
2021
Q2 		$1.27M Buy
46,906
+7,108
+18% +$174K ﹤0.01% 1957
2021
Q1 		$931K Sell
39,798
-4,520
-10% -$91.4K ﹤0.01% 2090
2020
Q4 		$679K Sell
44,318
-17,100
-28% -$217K ﹤0.01% 2107
2020
Q3 		$741K Buy
61,418
+9,600
+19% +$91.1K ﹤0.01% 1940
2020
Q2 		$527K Sell
51,818
-611,507
-92% -$6.3M ﹤0.01% 2027
2020
Q1 		$6.92M Buy
663,325
+30,988
+5% +$389K ﹤0.01% 1289
2019
Q4 		$10.1M Buy
632,337
+89,591
+17% +$1.37M ﹤0.01% 1310
2019
Q3 		$10M Sell
542,746
-65,005
-11% -$1.27M ﹤0.01% 1293
2019
Q2 		$12M Buy
607,751
+129,497
+27% +$2.64M ﹤0.01% 1287
2019
Q1 		$10.9M Buy
478,254
+4,439
+0.9% +$96.4K ﹤0.01% 1306
2018
Q4 		$9.54M Buy
473,815
+1,601
+0.3% +$33.1K ﹤0.01% 1317
2018
Q3 		$10.3M Sell
472,214
-10,082
-2% -$224K ﹤0.01% 1367
2018
Q2 		$10.7M Buy
482,296
+8,440
+2% +$173K ﹤0.01% 1333
2018
Q1 		$8.17M Buy
473,856
+78,704
+20% +$1.31M ﹤0.01% 1367
2017
Q4 		$6.57M Buy
395,152
+218,600
+124% +$3.73M ﹤0.01% 1399
2017
Q3 		$3.02M Buy
176,552
+161,650
+1,085% +$2.72M ﹤0.01% 1504
2017
Q2 		$242K Buy
+14,902
New +$236K ﹤0.01% 2311
2015
Q4 		– Sell
-11,932
Closed -$157K – 2515
2015
Q3 		$157K Hold
11,932
– – ﹤0.01% 2336
2015
Q2 		$196K Hold
11,932
– – ﹤0.01% 2353
2015
Q1 		$212K Hold
11,932
– – ﹤0.01% 2331
2014
Q4 		$227K Hold
11,932
– – ﹤0.01% 2300
2014
Q3 		$164K Hold
11,932
– – ﹤0.01% 2389
2014
Q2 		$195K Hold
11,932
– – ﹤0.01% 2355
2014
Q1 		$188K Hold
11,932
– – ﹤0.01% 2335
2013
Q4 		$205K Hold
11,932
– – ﹤0.01% 2306
2013
Q3 		$158K Hold
11,932
– – ﹤0.01% 2318
2013
Q2 		$135K Buy
+11,932
New +$127K ﹤0.01% 2284

Other funds holding ANGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
BH
Broadfin Holdings Melville, New York $23.5M AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
WCM
Weber Capital Management San Francisco, California $100M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BAM
Bastion Asset Management Montreal, Canada $328M AUM 13.57% 1-Year Est. Return

T. Rowe Price Associates's ANGO Position: Q1 2026 in Review

T. Rowe Price Associates increased its AngioDynamics (ANGO) stake by 10% in Q1 2026, buying an estimated $47.8K and bringing the position to 48,712 shares worth $554K. The position accounts for ﹤0.01% of the portfolio, ranked #2404.

T. Rowe Price Associates first reported a position in ANGO in Q2 2013 and has held it in 46 quarters since. The position peaked at $12M in Q2 2019. 147 funds tracked by Wall St. Rank hold ANGO as of Q1 2026.

  • T. Rowe Price Associates held 48,712 shares of AngioDynamics worth $554K as of Q1 2026.
  • T. Rowe Price Associates bought 4,414 AngioDynamics shares in Q1 2026, an estimated $47.8K.
  • AngioDynamics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2404 holding.
  • T. Rowe Price Associates first reported a position in AngioDynamics in Q2 2013 and has held it in 46 quarters since.
  • T. Rowe Price Associates's AngioDynamics position peaked at $12M in Q2 2019.
  • 147 funds tracked by Wall St. Rank held AngioDynamics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.